Soluble inhibitors of vascular endothelial growth factor and...

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S185100

Reexamination Certificate

active

10104610

ABSTRACT:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

REFERENCES:
patent: 6204011 (2001-03-01), Kendall et al.
patent: WO94/11499 (1994-05-01), None
patent: WO95/33050 (1995-12-01), None
patent: WO96/40769 (1996-12-01), None
Yamada et al, Blood 97(6): 1671-8, 2001.
Bodey et al, Anticancer Research 20: 2665-2676, 2000.
Ezzell et al, Journal of NIH Research 7: 46-49, 1995.
Spitler et al, Cancer Biotherapy 10: 1-3, 1995.
Soker et al, J Biol Chem 272(50): 31582-88, Dec. 12, 1997.
Dermer et al, Bio/Technology 12: 320, 1994.
Gura et al, Science 278: 1041-1042, Nov. 1997.
T. Omura et al., “Identification of a 190 kDa Vascular Endothelial Growth Factor 165 Cell Surface Binding Protein on a Human Glioma Cell Line,” J. Biol. Chem., 272(37):23317-23322, 1997.
S. Soker et al., “Neuropilin-1 is expressed by endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor,” Cell, 92:735-745, 1998.
S. Soker et al., “Characterization of Novel Vascular Endothelial Growth factor (VEGF) Receptors on Tumor Cells that Bind VEGF165 Via it Exon 7-Encoded Domain,” J. Biol. Chem., 271(10): 5761-5767, 1996.
H. Chen et al., “Neuropilin-2, A Novel Member of the Neuropilin Family, is a High Affinity receptor for the Semaphorins sema E and sema IV but not sema III,” Neuron, 19:547-559, 1997.
A. L. Kolodkin et al., “Neuropilin is a Semaphorin III Receptor,” Cell, 90:753-762, 1997.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Soluble inhibitors of vascular endothelial growth factor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble inhibitors of vascular endothelial growth factor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble inhibitors of vascular endothelial growth factor and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3801101

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.